NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Significant Decrease in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 555,312 shares, a drop of 18.5% from the December 15th total of 681,153 shares. Based on an average trading volume of 293,318 shares, the short-interest ratio is presently 1.9 days. Based on an average trading volume of 293,318 shares, the short-interest ratio is presently 1.9 days.

NeuroSense Therapeutics Stock Performance

NRSN traded up $0.07 during midday trading on Tuesday, hitting $1.02. The company had a trading volume of 367,752 shares, compared to its average volume of 241,887. NeuroSense Therapeutics has a twelve month low of $0.68 and a twelve month high of $2.60. The company has a market capitalization of $13.94 million, a PE ratio of -1.89 and a beta of 1.62. The firm’s 50-day simple moving average is $0.97 and its 200-day simple moving average is $1.22.

Analyst Upgrades and Downgrades

NRSN has been the topic of several research reports. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Monday, December 22nd. Zacks Research raised shares of NeuroSense Therapeutics to a “hold” rating in a report on Wednesday, October 15th. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Finally, Noble Financial raised NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Jane Street Group LLC bought a new position in NeuroSense Therapeutics in the second quarter valued at approximately $54,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares during the period. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.